News Releases Year None20242023202220212020201920182017 NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 Sep 14, 2024 NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study Aug 29, 2024 NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 15, 2024 NuCana to Present at the Jefferies Global Healthcare Conference May 30, 2024 NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit May 21, 2024 NuCana Reports First Quarter 2024 Financial Results and Provides Business Update May 16, 2024 NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement May 01, 2024 NuCana Announces Completion of ADS Ratio Change Apr 16, 2024 NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study Apr 09, 2024 NuCana Announces Plan to Implement ADS Ratio Change Mar 27, 2024 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 Sep 14, 2024
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study Apr 09, 2024